We have collected information about Oral Colon-Specific Drug Delivery Of Protein And Peptide Drugs for you. Follow the links to find out details on Oral Colon-Specific Drug Delivery Of Protein And Peptide Drugs.
https://www.ncbi.nlm.nih.gov/pubmed/17430100
Crit Rev Ther Drug Carrier Syst. 2007;24(1):63-92. Oral colon-specific drug delivery of protein and peptide drugs. Sinha V(1), Singh A, Kumar RV, Singh S, Kumria R, Bhinge J.Author: Vivek Ranjan Sinha, Asmita Singh, Ruchita V. Kumar, Sanjay Singh, Rachana Kumria, J. R. Bhinge
http://dl.begellhouse.com/journals/3667c4ae6e8fd136,4e98f23177ff4020,30e5f0bb1cd893a9.html
This review also includes studies conducted on colonic targeting of such drugs. Further studies may lead to improvements in therapy using protein/peptide drugs and refinements in the technology of colon-specific drug delivery.
https://www.sciencedirect.com/science/article/abs/pii/0169409X9190051D
The colon is also a potential site for absorption of peptides and proteins. Some potential limitations involved in oral peptide and protein delivery from the colon are discussed. In addition, the use of specific receptors and lectins on colonic mucosal cells offer the potential to deliver drugs to the colonic mucosa in a selective way.Author: David R. Friend
https://www.sciencedirect.com/science/article/pii/S0168365903004139
Colon-specific drug delivery systems (CDDSs) can be used to improve the bioavailability of protein and peptide drugs through the oral route. A novel formulation for oral administration using coated calcium alginate gel beads-entrapped liposome and bee venom peptide as a model drug has been investigated for colon-specific drug delivery in vitro.Author: Liu Xing, Liu Xing, Chen Dawei, Xie Liping, Zhang Rongqing
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2792531/
Consequently, the absolute oral bioavailability levels of most peptides and proteins are less than 1%. The challenge here is to improve the oral bioavailability from less than 1% to atleast 30-50%. Designing and formulating a protein and peptide drug for delivery though GI …
https://link.springer.com/article/10.1208/s12249-019-1325-z
May 20, 2019 · Colon-Specific Drug Delivery. Protein and peptide drugs may be degraded under the condition of partial acidity or partial alkalinity, so the intestinal release in theory in a near-neutral environment is beneficial to protect the activity of protein and peptide drugs . At the end of the gastrointestinal tract in the colon, the first-pass effect is avoided since the enzyme activity in the colon …
https://link.springer.com/article/10.2165/00063030-200519030-00003
Aug 15, 2012 · The main reasons for the low oral bioavailability of peptide drugs are pre-systemic enzymatic degradation and poor penetration of the intestinal mucosa. A considerable amount of research has focused on overcoming the challenges presented by these intestinal absorption barriers to provide effective oral delivery of peptide and protein drugs.Author: Josias H. Hamman, Gill M. Enslin, Awie F. Kotzé
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3215502/
Feb 07, 2010 · Targeted drug delivery into the colon is highly desirable for local treatment of a variety of bowel diseases such as ulcerative colitis, Crohn’s disease, amebiosis, colonic cancer, local treatment of colonic pathologies, and systemic delivery of protein and peptide drugs.1, 2 The colon specific drug delivery system (CDDS) should be capable of protecting the drug en route to the colon i.e. drug release …Author: Anil K. Philip, Betty Philip
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4908063/
Jun 16, 2014 · Although the oral delivery of proteins and peptides remains an attractive option, but to reach its true potential the challenges must be met. Oral delivery of proteins and peptides has long been hailed as the ‘Holy Grail’ of drug delivery by showing great potential but also presenting problems in their development .Author: Abdul Muheem, Faiyaz Shakeel, Mohammad Asadullah Jahangir, Mohammed Anwar, Neha Mallick, Gaurav Kuma...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4508299/
Jun 13, 2015 · Colon-specific drug delivery systems (CDDS) are desirable for the treatment of a range of local diseases such as ulcerative colitis, Crohn’s disease, irritable bowel syndrome, chronic pancreatitis, and colonic cancer. In addition, the colon can be a potential site for the systemic absorption of several drugs to treat non-colonic conditions.Author: Seth Amidon, Jack E. Brown, Vivek S. Dave
Searching for Oral Colon-Specific Drug Delivery Of Protein And Peptide Drugs?
You can just click the links above. The data is collected for you.
